205 related articles for article (PubMed ID: 2466128)
21. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment.
Rönnblom LE; Alm GV; Oberg K
Acta Oncol; 1991; 30(4):537-40. PubMed ID: 1854511
[TBL] [Abstract][Full Text] [Related]
23. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour.
Rönnblom LE; Alm GV; Oberg KE
J Intern Med; 1990 Mar; 227(3):207-10. PubMed ID: 1690258
[TBL] [Abstract][Full Text] [Related]
24. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.
Schöber C; Schmoll E; Schmoll HJ; Poliwoda H; Schuppert F; Stahl M; Bokemeyer C; Wilke H; Weiss J
Eur J Cancer; 1992; 28A(10):1664-6. PubMed ID: 1382494
[TBL] [Abstract][Full Text] [Related]
25. Metastatic carcinoid tumors and the malignant carcinoid syndrome.
Kvols LK
Ann N Y Acad Sci; 1994 Sep; 733():464-70. PubMed ID: 7978896
[No Abstract] [Full Text] [Related]
26. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect?
Dirix LY; Vermeulen PB; Fierens H; De Schepper B; Corthouts B; Van Oosterom AT
Anticancer Drugs; 1996 Feb; 7(2):175-81. PubMed ID: 8740722
[TBL] [Abstract][Full Text] [Related]
27. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon.
Moertel CG; Rubin J; Kvols LK
J Clin Oncol; 1989 Jul; 7(7):865-8. PubMed ID: 2738623
[TBL] [Abstract][Full Text] [Related]
28. Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report.
Hanssen LE; Schrumpf E; Kolbenstvedt AN; Tausjø J; Dolva LO
Acta Oncol; 1989; 28(3):439-43. PubMed ID: 2742781
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases].
Votte A; Iglicki F; Sévenet F; Tabah I; Dupas JL
Presse Med; 1996 Jan; 25(2):63-7. PubMed ID: 8745720
[TBL] [Abstract][Full Text] [Related]
30. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
31. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ
Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635
[TBL] [Abstract][Full Text] [Related]
32. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
34. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
36. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
37. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
38. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.
Yao JC; Guthrie KA; Moran C; Strosberg JR; Kulke MH; Chan JA; LoConte N; McWilliams RR; Wolin EM; Mattar B; McDonough S; Chen H; Blanke CD; Hochster HS
J Clin Oncol; 2017 May; 35(15):1695-1703. PubMed ID: 28384065
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
Andreyev HJ; Scott-Mackie P; Cunningham D; Nicolson V; Norman AR; Badve SS; Iveson A; Nicolson MC
J Clin Oncol; 1995 Jun; 13(6):1486-92. PubMed ID: 7751896
[TBL] [Abstract][Full Text] [Related]
40. Extended experience with recombinant alpha-2b interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report.
Hanssen LE; Schrumpf E; Jacobsen MB; Kolbenstvedt AN; Kolmannskog F; Bergan A; Dolva LO
Acta Oncol; 1991; 30(4):523-7. PubMed ID: 1854510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
